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Abstract 
Background 
Liver disease is a major cause of mortality with high hospital death and 
disproportionately affects people under 65. This study aims to examine the 
place of death and factors associated with hospital death for those who died 
from liver disease. 
Methods 
Population-based observational study using the National Death Registration 
Database from the Office for National Statistics, 2001–2014. All non-accidental 
adult deaths (hospital and non-hospital) from liver disease in England were 
included. Explanatory variables were underlying cause of death, contributory 
causes of death (number and specific causes), age at death, sex, marital status, 
year of death, index of multiple deprivation, rural/urban settlement and 
residential region. Modified Poisson regression models were applied to 
evaluate the strength of association between hospital death and explanatory 
variables using adjusted prevalence ratio (PR). 
Findings 
A total of 135,953 decedents were included, and 56,065 (41·2%) of them died 
from alcoholic liver disease. The annual deaths from liver disease increased 
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from 7,811 in 2001 to 11,017 in 2014. Hospital was the main place of death 
(66·9%, 95% confidence interval 66.6%–67.1%) for patients who died from liver 
disease. The proportion of hospital deaths reduced from 71·5% (2001) to 
60·0% (2014). After adjusting sociodemographic factors, patients who died 
from alcoholic liver disease had the highest chance of hospital death; those 
from liver cancer were less likely to die in hospital (PR 0·61, 95% confidence 
interval [95%CI] 0·60–0·61, reference: alcoholic liver disease). Those with 
more contributory causes of death (PR 1·45, 95%CI 1·42–1·47, 4+ versus 0) 
were more likely to die in hospital. Patients with sepsis (PR 1·24, 95%CI 1·23–
1·25), hepatorenal syndrome (PR 1·22, 95%CI 1·21–1·22), and peritonitis (PR 
1·18, 95%CI 1·17–1·20) had higher, and those with alcohol related disorders 
(PR 0·67, 95%CI 0·66–0·69) had lower chances of hospital death, respectively. 
Interpretation 
The annual deaths from liver disease increased steadily in England, and 
alcoholic liver disease was the commonest underlying cause of death. Patients 
with sepsis, hepatorenal syndrome, or peritonitis were associated with high 
hospital death, which warrants further investigation. The reasons for the 
disproportionately low hospital death in patients with alcohol related disorders 
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need to be explored. There is a dire need for prevention strategies as well as 
end of life care services to prevent and tackle harms from liver disease.  
Funding 
NIHR HS&DR programme, CLAHRC South London 
 
Keywords 
Liver disease; hospital death; cause of death; end of life care; alcoholic liver 
disease; sepsis; hepatorenal syndrome; alcohol related disorders 
 
Research in context 
Evidence before this study 
Liver disease is a common cause of mortality, and the number of people who 
died from liver disease in the under 65s in UK is still on the increase. However, 
there is a lack of information about the place of death and factors associated 
with hospital death for those who died from liver disease in the UK. 
Added value of this study 
This population-based observational study included a total of 135,953 
decedents in England who died from liver disease from the Office for National 
Statistics, 2001–2014. The commonest underlying cause of death was 
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alcoholic liver disease. Hospital was the main place of death for patients who 
died from liver disease. Patients who died from alcoholic liver disease had the 
highest chance of hospital death. Those with more contributory causes of death 
were more likely to die in hospital. Patients with sepsis, hepatorenal syndrome, 
and peritonitis had higher, and those with alcohol related disorders had lower 
chances of hospital death, respectively. 
Implications of all the available evidence 
Our study provides a good reference for developing tailored care services for 
people dying from liver disease. Among the whole study population, those who 
were with sepsis, hepatorenal syndrome, or peritonitis were associated with 
high hospital death, which warrants further investigation. The reasons for the 
disproportionately low hospital death in patients with alcohol related disorders 
need to be explored. There is a dire need for prevention strategies as well as 
end of life care services to prevent and tackle harms from liver disease. 
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Background 
Liver disease is a common cause of mortality, accounting for 2% of all deaths 
worldwide according to a global estimate in 2010 (1, 2). In Europe, liver disease 
is the seventh leading cause of death (3). In the United States, the percentage 
of those who died from chronic liver disease, cirrhosis, and liver cancer was 
2·4% in 2014 (4, 5). Similarly, about 2% of deaths in the United Kingdom (UK) 
were from a liver disease (6, 7). In the UK, liver disease is currently the 5th most 
common cause of death in those under 65 years of age, and the number of 
people who die from end-stage liver disease is still increasing (8). Compared to 
other organ failure or terminal illness, liver disease disproportionately affects 
people under 65 years old, hence becoming one of the largest causes of 
premature mortality (7, 8). 
 
While deaths from liver disease have been decreasing in other European 
countries, the number of people who died from liver disease in the under 65s in 
UK is still on the increase (8). It reveals an urgent need to gather more evidence 
and to take actions against liver disease (9-11). Furthermore, the National End 
of Life Care Programme in the UK (12, 13) has successfully shifted the place 
of death, a common population-based marker of care quality, of patients with 
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cancer from hospitals to people’s homes gradually since 2005 (14-16). 
However, whether the policy changed the care for those dying from liver 
disease remains unexplored. Lastly, patients dying from liver disease are likely 
to have specific end of life care needs (7), yet there is a lack of information 
about the last days of life of these patients and what they die from. Given the 
strength in nationwide coverage and data accuracy, the death registration data 
from the Office for National Statistics (ONS) has been well utilised in analysing 
place of death and its associated factors (14, 17-20). In addition, contributory 
causes of death from ONS data, which can be seen as complications or 
comorbidities contributing to a patient’s death, provide important contextual 
information of patients who die from liver disease. 
 
The aim of this study is to examine the place of death and factors associated 
with hospital death for those who died from liver disease in England, in the 
context of their socio-demographic characteristics. 
 
Methods 
Study design and setting 
A population-based observational study in England, 2001–2014. 
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Data source 
The ONS collected data from all death registrations in England, which included 
decedents’ age of death, sex, marital status, residential region, place and year 
of death, underlying and contributory causes of death, recorded using the 10th 
edition of International Classification of Diseases (ICD-10) codes. The ONS 
death registration database was linked with area level indices of multiple 
deprivation (IMD), which is the official measure of relative deprivation for small 
areas in England. The IMD combines seven domains of deprivation using the 
following weights: income, employment, health deprivation and disability, 
education skills and training, barriers to housing and services, crime, and living 
environment (21, 22). The unit for IMD calculation is the lower layer super 
output area (LSOA), which is a low-level geographic area designed for reporting 
small area statistics. In England, there were 32,482 LSOAs in 2001 and 32,844 
LSOAs in 2011 according to the census data. All LSOAs were grouped into 
quintiles based on the rank of their IMD scores (22, 23). 
 
Study population 
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All non-accidental adult decedents (>=18-year-old) with liver disease as the 
underlying cause of death between 2001 and 2014 in England were included 
for this study. The definition of liver disease underlying causes of death by ICD-
10 codes is: alcoholic liver disease (K70), fatty liver disease (K760), viral liver 
disease (B15–B19), other chronic liver disease (I81, I85, K71–K75, K761–
K769, K77), and liver cancer (C22) (7). Disorders of gallbladder, biliary tract 
and pancreas (K80–K87), though likely to present with abnormal liver function 
test or jaundice, were not considered because this group were too broad to be 
discerned if the disorder was truly related to liver (7). 
 
Variables 
The study outcome was hospital death, inclusive of all deaths in NHS and non-
NHS hospitals. Non-hospital deaths were categorised into 4 groups: home, 
hospice, care home (including nursing home, residential home, and care 
home), and elsewhere. The main explanatory variables were underlying cause 
of death (alcoholic liver disease, fatty liver disease, viral liver disease, other 
chronic liver disease, and liver cancer), contributory causes of death – number 
& specific cause of death. Number of contributory causes was grouped into 5 
groups: 0, 1, 2, 3, 4+ (4 or more). We planned to extract six liver disease related 
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complications, including esophageal varices, hepatic encephalopathy, 
spontaneous bacterial peritonitis, ascites, hepatorenal syndrome, and 
hepatopulmonary syndrome (24). However, hepatic encephalopathy was not 
clearly defined in ICD-10, so we applied encephalopathy (G93.4) as a surrogate 
for hepatic encephalopathy. In addition, we found there was no record of 
spontaneous bacterial peritonitis (ICD-10: K65.5) in the database, so we 
broadened the code to K65 (peritonitis) as a surrogate for spontaneous 
bacterial peritonitis. Chronic comorbidities were collected with reference to the 
Charlson comorbidity index, inclusive of cardiovascular disease (acute 
myocardial infarction, congestive heart failure, and peripheral vascular 
disease), neurological conditions (cerebral vascular disease and paraplegia), 
dementia, pulmonary disease, connective tissue disease, peptic ulcer disease, 
diabetes mellitus (diabetes and related complications), renal disease, and non-
liver or metastatic cancer (25, 26). We explored the database and identified 
other 3 most frequently reported contributory causes of death: sepsis (A41), 
influenza and pneumonia (J09–J18), and alcohol related disorders (F10). 
 
The contextual socio-demographic variables included: age of death (18–34, 
35–44, 45–54, 55–64, 65–74, 75–84, 85+), sex (male, female), marital status 
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(married, single, widowed or widow from civil partnership, divorced or separated 
or dissolved civil partnership, and unknown or not stated), year of death (2001–
2004, 2005–2008, 2009–2014), IMD quintiles (1–most deprived to 5–least 
deprived), settlement (urban, rural), and residential region (London, South East, 
South West, East of England, East Midlands, West Midlands, Yorkshire and 
The Humber, North East, North West). We analysed age as an ordered 
categorical variable rather than a continuous variable to facilitate interpretation 
and comparison with other studies. The year of death was divided into 3 
intervals based on the launch, implementation, and roll-out of several national 
initiatives for improving end-of-life care in the UK. The 3 intervals were: 2001–
2004 (pre-strategy), 2005–2008 (strategy launch & intensification phase), and 
2009–2014 (post-strategy) (12, 13). We used IMD 2004, IMD 2007 and IMD 
2010 to map the residential area-based deprivation of the decedents for the 
period 2001–2004, 2005–2007 and 2008–2014 respectively. The rural/urban 
settlement was classified using 2001 Census data for those who died between 
2001 and 2010, and 2011 Census data for those who died between 2011 and 
2014. 
 
Statistical analysis 
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Variables in the study were described primarily as categorical data using count 
and percentage. Bivariate analyses were performed to check if there was an 
association between each explanatory variable and hospital death. The 
statistical significance was assessed using the chi-squared test. Modified 
Poisson regression models with robust variance were applied to evaluate the 
independent association between hospital death and potential explanatory 
variables, and only those which were statistically significant in bivariate analysis 
(p<0·05) were included in the multivariate modelling. The strength of 
association was measured using prevalence ratio (PR), which is a measure of 
relative risk, estimated from multivariate models. In this way, we avoided the 
overestimation of association caused by using odds ratio (27, 28). Potential 
interaction between variables were explored and tested, and sensitivity analysis 
was carried out by running separate models omitting one of the concerned 
variables or taking interactions into consideration. In addition, we plotted the 
proportion of hospital deaths by year, stratified by underlying cause of death, 
numbers of contributory cause of death, and other explanatory variables as 
appropriate. Stata/SE 14 (STATA, College Station, TX) was used for all 
analyses. 
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Role of the funding source 
The funders had no role in study design, data collection and analysis, decision 
to publish, or preparation of the manuscript. The views and opinions expressed 
therein are those of the authors and do not necessarily reflect those of the 
HS&DR programme, NIHR, NHS, or the Department of Health. No author was 
paid to write this article by a pharmaceutical company or other agency. All 
authors (JKP, IJH, WG) had full access to the raw data in the study. The 
corresponding author (JKP) had full access to all of the data and the final 
responsibility to submit for publication. 
 
Results 
Between 2001 and 2014 in England, a total of 135,953 adults died from liver 
disease, representing 2·1% of the total 6,368,760 non-accidental deaths during 
this period. Among them, 90,921 (66·9%, 95% confidence interval [CI] 66.6%–
67.1%) died in hospital, while the other 45,032 (33.1%, 95% CI 32.9%–33.4%) 
died in a non-hospital setting (home [21·9%], hospice ([5·5%]), care home 
([4·3%]), and elsewhere [1·3%]) (Table 1). The annual deaths from liver disease 
increased steadily from 7,811 in 2001 to 11,017 in 2014 (Figure 1). The 
proportion of hospital death was stable initially (71·5% in 2001) and then 
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decreased constantly after 2004/2005 following the national policies of 
improving end of life care and facilitating home death (in 2014: 60·0%, see 
Figure 1). There were no missing data in all variables except marital status. The 
marital status of 1,995 (1.5%) decedents was missing and was categorized as 
“unknown or not stated”. We analysed them as a category rather than deleting 
them. 
 
The socioeconomic characteristics of the study population are shown in Table 
1. The mean age of death was 62·8 (standard deviation (SD) 14·6). There were 
more men (61·5%) than women (38·5%). Two fifth of the decedents were 
married (42·7%), followed by divorced (or separated or dissolved civil 
partnership, 20·2%), single or widowed (18·0% each), and unknown or not-
stated (1·5%). There were relatively more decedents from deprived areas. 
Those who were classified as the most deprived (IMD quintile 1) and the least 
deprived (IMD quintile 5) accounted for 30·2% and 13·4%, respectively.  
 
The clinical characteristics of the study population are shown in Table 2. 56,065 
(41·2%) decedents died from alcoholic liver disease, followed by liver cancer 
(29·0%), other chronic disease (24·7%), fatty liver disease (3·0%), and viral 
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liver disease (2·1%). Those who had more contributory causes of death were 
more likely to die in the hospital, ranging from 50·7% (number of contributory 
causes of death: 0) to 83·5% (number of contributory causes of death: 4 or 
more). The most frequent contributory cause of death was influenza and 
pneumonia (12·7%), followed by esophageal varices (7·0%), cardiovascular 
disease (6·9%), and cancer (non-liver or metastatic, 6·7%). 
 
Results of multivariate analysis for factors associated with hospital death are 
presented in Table 3. Increased age (55 years or above) and female sex were 
associated with a higher chance of hospital death. Those who were not married, 
died in 2005–2008 or 2009–2014, lived in a rural settlement, and were less 
deprived were less likely to die in hospital. The decedents had a lower chance 
of hospital death if they didn’t live in London. 
 
The underlying cause of death was also associated with hospital death (Table 
3). Compared to those who died from alcoholic liver disease, viral liver disease 
(adjusted PR 0·96, 95% confidence interval 0·95–0·98) and other chronic liver 
disease (PR 0·85, 0·84–0·86) were associated with slightly fewer hospital 
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deaths, although this was a larger degree for those who died from fatty liver 
disease (PR 0·52, 0·50–0·54) and liver cancer (PR 0·61, 0·60–0·61).  
 
The association between contributory causes of death and hospital death is 
presented in Table 3. There was a significant association between the number 
of contributory causes of death and hospital death, and a dose-response 
relationship was noted. Compared to those who had no contributory cause of 
death, the PRs of hospital death in decedents with 1, 2, 3, and 4+ medical 
conditions were 1.20 (1·18–1·21), 1·24 (1·22–1·26), 1·32 (1·31–1·34), and 
1.45 (1·42–1·47). Those who had sepsis (PR 1·24, 1·23–1·25), hepatorenal 
syndrome (PR 1·22, 1·21–1·22), and peritonitis (PR 1·18, 1·17–1·20) were 
more likely to die in hospital. On the contrary, decedents with alcohol related 
disorders (PR 0·67, 0·66–0·69), dementia (PR 0·77, 0·73–0·82), and non-liver 
or metastatic cancer (PR 0·80, 0·78–0·81) had a lower chance of hospital 
death. 
 
Figure 2 demonstrates the time trend of the proportion of hospital death 
stratified by underlying cause of death, number of contributory causes of death, 
and the selected contributory cause of death. A markedly increasing trend of 
17 
 
hospital death in patients with fatty liver disease was noted (from 24·3% in 2001 
to 53·8% in 2014), while those who died from liver cancer had a persistently 
low and decreasing percentage of hospital death. For those who had no 
contributory cause of death, hospital death markedly decreased following the 
plateau in 2001–2005. In contrast, those who had 4 or more contributory causes 
of death were still highly likely to die in hospital. The dose-response relationship 
became more pronounced over these years. The presence of sepsis, 
hepatorenal syndrome, and peritonitis was individually associated with 
consistently high hospital deaths (all greater than 90% during 2001–2014). For 
those with alcoholic liver disease as the underlying cause of death, alcohol 
related disorders played an important role in place of death. The chance of 
hospital death was significantly lower if they had these kinds of mental or 
behavioural disorders as their contributory cause of death. 
 
Discussion 
To our knowledge, this is the first population-based study assessing hospital 
death and its determinants, particularly the underlying and contributory causes 
of death, in liver disease. Hospital was the most common place of death for 
patients who died from liver disease. The number of contributory causes of 
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death was independently associated with higher hospital deaths. Patients who 
died with sepsis, hepatorenal syndrome, or peritonitis had an increased chance 
of hospital death, whilst those with alcohol related disorders, dementia, non-
liver or metastatic cancer had a lower chance of hospital death. 
 
Our study revealed the annual deaths from liver disease increased markedly in 
England, and alcoholic use is the leading factor for death in this population, 
which is consistent with previous studies (7, 9, 29, 30). Globally, alcohol plays 
an important role in global disease burden and results in tremendous health 
loss (30-33). It is crucial to reduce overall alcohol consumption in both 
population and individual level (9, 31, 34, 35). While looking into the evolution 
or trend between 2001 and 2014, some information is worth being noted (see 
appendix table and figures). Firstly, those who died from liver cancer doubled 
during this period, which indicated the importance of prevention and early 
detection of liver cancer. And as a result, the age of death increased 
simultaneously because the mean age of death of those who died from liver 
cancer was 72.3-year-old, which is higher than those who died from alcoholic 
liver disease (mean 54.8-year-old), fatty liver disease (mean 57.7-year-old), 
viral liver disease (mean 58.7-year-old), and other chronic liver disease (mean 
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65.8-year-old). Secondly, the deaths increased in both male and female sex, 
and female decedents accounted for 38–39% constantly during these years. 
Thirdly, considering residential region, a marked increase was noted in East 
Midlands (66%) and East of England (65%) (compared 2014 to 2001), while the 
increase in London was just about 5%. The ecological effect requires 
exploration. 
 
Though rarely studied before, the information on contributory causes of death 
of patients dying from liver disease is valuable and can help us understand 
more about the medical problems that these decedents were facing or that 
initiated their end of life journey. Accordingly, how to deal with these problems 
properly becomes important, especially while the policy is committed to help 
these patients be cared for or to die in the place they prefer. At this point, 
collaboration between general practitioners, hepatologists, transplantation 
teams, and specialist palliative care is vital (11, 36-39). In addition, healthcare 
professionals can utilise these clinical and socioeconomic factors to identify 
those who are at a higher risk of hospital death and provide appropriate care 
and timely intervention. However, for each individual patient, “hospital death” 
itself doesn’t necessarily imply a “good” or “bad” outcome, or “appropriate” or 
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“not appropriate” care. On the one hand, if the patients choose to die at home, 
healthcare professionals need to address their needs and try to accomplish 
their wishes. On the other hand, if the medical problems need to be treated in 
a hospital setting, considering the best interest of these patients, they should 
have the opportunities to be cared for and treated in hospital, no matter if they 
eventually die in the hospital. 
 
Among the contributory causes of death associated with a higher risk of hospital 
death, infection (including sepsis, peritonitis, influenza and pneumonia) was a 
key factor. According to previous studies, sepsis was the most common reason 
for terminal hospitalisations in patients with decompensated liver disease (40). 
In addition, cirrhosis itself was strongly associated with increased risk of sepsis, 
sepsis-related mortality, acute respiratory failure, and acute respiratory failure-
related mortality (41). This may be because patients with cirrhosis are more 
susceptible to infection owing to immunologic deficits (42, 43). While infection 
is seen as a common pathway leading to death, it does not necessarily mean 
that nothing can be done to improve the care for patients with advanced liver 
disease. For example, good infection control and judicious use of invasive 
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interventions in these patients may help to reduce the risk of secondary 
infection during their hospitalisations (42). 
 
Renal failure (hepatorenal syndrome and chronic renal disease) was also a key 
factor associated with higher hospital deaths in our study, which is consistent 
with the result of a study of medical intensive care unit mortality in cirrhotic 
patients (44). Hepatorenal syndrome is a major complication resulting in renal 
failure in patients with advanced liver disease, which is defined as the end stage 
of the reductions in renal perfusion owing to severe hepatic injury (45-47). The 
prognosis of hepatorenal syndrome is poor, and many patients die several 
weeks after its onset if there is no adequate treatment (48). Notably, a recent 
study in Korea compared the causes of in-hospital death in patients with end-
stage liver disease between 2002 and 2011. During these years, some of the 
complications caused by end-stage liver disease had been better treated and 
were less likely to cause in-hospital death, such as: variceal bleeding, hepatic 
encephalopathy, ascites, and spontaneous bacterial peritonitis. However, 
hepatorenal syndrome was still difficult to be treated and accounted for 34.7% 
of the causes of in-hospital death in 2011 (16·9% in 2002) (49). As illustrated 
in our study, those who had hepatorenal syndrome as their contributory cause 
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of death were constantly and highly likely (>90%) to die in hospital over this 14-
year period. So far, hepatorenal syndrome is still a challenge in the health care 
for patients with advanced liver disease. 
 
Patients with non-liver or metastatic cancer and dementia as their contributory 
causes of death had a markedly lower chance of hospital death in our study. It 
is not surprising that non-liver or metastatic cancer was associated with a lower 
chance to die in hospital, given that the palliative care services for patients with 
cancer are more established than for those patients with non-cancer conditions 
(12, 13). Among all decedents who had non-liver or metastatic cancer as their 
contributory cause of death in our dataset, 46·9% died in the hospital, followed 
by home (30·5%) and hospice (12·9%). The results were similar to a previous 
population-based study focusing on place of cancer death in England (14). It is 
also reasonable that dementia was associated with lower hospital death in 
England, since patients with dementia in England were more likely to die in care 
homes rather than hospitals. According to a population-based study of 388,899 
decedents with dementia in England, 55·3% of them died in care homes, and 
39·6% of them died in hospitals (19). So, if patients died from liver disease 
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cormobid with dementia, they were less likely to die in hospital compared to 
those without dementia in England. 
 
A noteworthy finding was the disproportionately low hospital deaths in patients 
with alcohol related disorders. Alcohol related disorders, by definition, are 
disorders related to or resulting from abuse or misuse of alcohol, which are 
classified in the group of mental and behavioural disorders due to psychoactive 
substance use. Alcohol related disorders are presented with one or mixed types 
of the following clinical conditions, inclusive of acute intoxication, harmful use, 
dependence syndrome, withdrawal state (with or without delirium), psychotic 
disorder, amnesic syndrome, residual and late-onset psychotic disorder, and 
other mental and behavioural disorders (50). Patients with alcohol related 
disorders may also use more than one psychoactive substance, which 
complicates the illness and makes the health care more challenging (51). These 
patients need more attention, and further studies in the following areas may be 
helpful, including the healthcare utilisation patterns (especially emergency 
department attendance and hospitalisation), the type of care during their end of 
life, the supportive system for them, their health literacy about liver disease and 
alcohol use, and their view and preference in terms of end of life care. 
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Our study has several limitations and the findings should be interpreted with 
caution. First, it is an observational study, so the causal relationship between 
contributory causes of death and hospital death cannot be established. Second, 
some findings related to socioeconomic characteristics from the data may be 
subject to ecological fallacy, which may not perfectly represent the real 
association between individuals within those groups. Third, the death certificate 
data lack some important information in, e.g. lifestyle, disease history, treatment 
course, hospital types, or healthcare utilisation patterns. Some of the above 
clinical information can be enriched via linking to other routinely collected data, 
such as the Clinical Practice Research Datalink (52) and/or the Hospital 
Episodes Statistics database (53). Furthermore, the proportion of hospital 
death and its trend are highly related to hospital bed capacity (54, 55). If the 
number of deaths increased but the provision of hospital didn’t grow, the 
proportion of hospital death could decrease year by year regardless of patients’ 
choice, socio-demographic factors, or clinical characteristics. In addition, 
studies using mortality statistics are at risk of certification bias (56). The 
comorbidities of patients are not always recorded in death certification data, 
and there is probably coding variation across different health care settings. 
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Also, since our study population was those who died from liver disease, we 
therefore excluded the patients with liver disease but otherwise who died from 
a non-liver-related cause (57) or died without cause of death recorded. Finally, 
the choice of ICD-10 codes and the application of surrogate codes (e.g. G93.4 
for hepatic encephalopathy, K65 for spontaneous bacterial peritonitis) could 
cause bias. 
 
Conclusions 
The annual deaths from liver disease increased steadily between 2001 and 
2014 in England. Alcoholic liver disease was the most common underlying 
cause of death. Two-thirds of people dying from liver disease eventually died in 
hospitals. Patients with sepsis, hepatorenal syndrome, or peritonitis were 
associated with high hospital death, which warrants further investigation. The 
reasons for the disproportionately low hospital death in patients with alcohol 
related disorders need to be explored. Last but not least, there is a dire need 
for prevention strategies as well as end of life care services to prevent and 
tackle harms from liver disease.  
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Figure 1. Number of deaths and proportion of hospital death in decedents who 
died from liver disease, England 2001–2014 
 
Figure 2. Time trends of proportion of hospital deaths for liver disease stratified 
by underlying cause of death, number of contributory causes of death, and the 
presence of several contributory causes of death (hepatorenal syndrome, 
sepsis, peritonitis, and alcohol related disorder given the underlying cause of 
death was alcoholic liver disease). 
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Table 1. Socioeconomic characteristics of the adult patients who died from liver disease in England, 2001–2014 
(N=135,953) 
Characteristics  Place of death 
   
 Total 
(N=135953) 
Hospital 
(N=90921) 
Non-hospital 
(N=45032) 
p-value 
   Home 
(N=29786) 
Hospice 
(N=7462) 
Care home 
(N=5866) 
Others 
(N=1918) 
 
 N (column %) N (row %) N (row %) N (row %) N (row %) N (row %)  
Age of death in years 
mean (SD) 
range 
 
62.8 (14.6) 
18–109 
 
61.8 (14.4) 
18–104 
 
61.7 (14.3) 
18–109 
 
69.1 (12.7) 
18–100 
 
77.2 (11.8) 
22–104 
 
58.2 (16.4) 
18–98 
 
<0.001 
 18-34 2946   (2.2) 2125 (72.1) 630 (21.4) 86 (2.9) 12 (0.4) 93 (3.2) <0.001 
 35-44 12759   (9.4) 9045 (70.9) 3057 (24.0) 227 (1.8) 67 (0.5) 363 (2.8)  
 45-54 26259 (19.3) 18680 (71.1) 6220 (23.7) 701 (2.7) 202 (0.8) 456 (1.7)  
 55-64 31758 (23.4) 22238 (70.0) 7156 (22.5) 1425 (4.5) 586 (1.8) 353 (1.1)  
 65-74 28942 (21.3) 19151 (66.2) 6279 (21.7) 2148 (7.4) 1119 (3.9) 245 (0.8)  
 75-84 23907 (17.6) 14424 (60.3) 4885 (20.4) 2184 (9.1) 2145 (9.0) 269 (1.1)  
 85+ 9382   (6.9) 5258 (56.0) 1559 (16.6) 691 (7.4) 1735 (18.5) 139 (1.5)  
        
Sex       <0.001 
 Male 83676 (61.5) 55417 (66.3) 19677 (23.5) 4375 (5.2) 2978 (3.6) 1229 (1.5)  
 Female 52277 (38.5) 35504 (67.9) 10109 (19.3) 3087 (5.9) 2888 (5.5) 689 (1.3)  
        
Marital status       <0.001 
 Married 58028 (42.7) 39211 (67.6) 12583 (21.7) 4120 (7.1) 1657 (2.9) 457 (0.8)  
 Single 24263 (17.8) 16450 (67.8) 5770 (23.8) 762 (3.1) 757 (3.1) 524 (2.2)  
 Widowed or widow from 
civil partnership 
24198 (17.8) 15230 (62.9) 4292 (17.7) 1619 (6.7) 2667 (11.0) 390 (1.6)  
 Divorced, separated, or 
dissolved civil partnership 
27469 (20.2) 18827 (68.5) 6506 (23.7) 923 (3.4) 735 (2.7) 478 (1.7)  
 Unknown or not stated  1995   (1.5) 1203 (60.3) 635 (31.8) 38 (1.9) 50 (2.5) 69 (3.5)  
        
Year of death       <0.001 
 2001-2004 33352 (24.5) 23790 (71.3) 6588 (19.8) 1330 (4.0) 1139 (3.4) 505 (1.5)  
 2005-2008 38010 (28.0) 26212 (69.0) 7957 (20.9) 1974 (5.2) 1376 (3.6) 491 (1.3)  
 2009-2014 64591 (47.5) 40919 (63.4) 15241 (23.6) 4158 (6.4) 3351 (5.2) 922 (1.4)  
        
Index of multiple 
deprivation quintile 
       
<0.001 
 1 (most deprived) 41009 (30.2) 28425 (69.3) 9057 (22.1) 1547 (3.8) 1308 (3.2) 672 (1.6)  
 2 29842 (22.0) 20214 (67.7) 6474 (21.7) 1462 (4.9) 1245 (4.2) 447 (1.5)  
 3 25093 (18.5) 16625 (66.3) 5451 (21.7) 1491 (5.9) 1187 (4.7) 339 (1.4)  
 4 21837 (16.1) 14085 (64.5) 4834 (22.1) 1486 (6.8) 1162 (5.3) 270 (1.2)  
 5 (least deprived) 18172 (13.4) 11572 (63.7) 3970 (21.8) 1476 (8.1) 964 (5.3) 190 (1.0)  
        
Settlement       <0.001 
 Urban 115150 (84.7) 77645 (67.4) 24822 (21.6) 6240 (5.4) 4799 (4.2) 1644 (1.4)  
 Rural 20803 (15.3) 13276 (63.8) 4964 (23.9) 1222 (5.9) 1067 (5.1) 274 (1.3)  
        
Residential region       <0.001 
 London 17882 (13.2) 12185 (68.1) 3692 (20.6) 1249 (7.0) 494 (2.8) 262 (1.5)  
 South East 19305 (14.2) 12514 (64.8) 4112 (21.3) 1503 (7.8) 910 (4.7) 266 (1.4)  
 South West 12597   (9.3) 8106 (64.3) 2928 (23.2) 758 (6.0) 631 (5.0) 174 (1.4)  
 East of England 12056   (8.9) 7746 (64.3) 2882 (23.9) 647 (5.4) 619 (5.1) 162 (1.3)  
 East Midlands 11261   (8.3) 7477 (66.4) 2381 (21.1) 453 (4.0) 781 (6.9) 169 (1.5)  
 West Midlands 15694 (11.5) 10921 (69.6) 3328 (21.2) 700 (4.7) 547 (3.5) 198 (1.3)  
 Yorkshire and The Humber 13758 (10.1) 9223 (67.0) 2874 (20.9) 784 (5.7) 678 (4.9) 199 (1.4)  
 North East 8756   (6.4) 5926 (67.7) 2013 (23.0) 267 (3.0) 421 (4.8) 129 (1.5)  
 North West 24644 (18.1) 16823 (68.3) 5576 (22.6) 1101 (4.5) 785 (3.2) 359 (1.5)  
 
  
Table 2. Clinical characteristics of the adult patients who died from liver disease in England, 
2001–2014 (N=135,953) 
Characteristics  Place of death 
 Total 
(column %)
Hospital 
(row %)
Non-hospital 
 (row %) 
p-value 
Underlying cause of death  <0.001
 Alcoholic liver disease 56065 (41.2) 44216 (78.9) 11849 (21.1) 
 Fatty liver disease 4071 (3.0) 1686 (41.4) 2385 (58.6) 
 Viral liver disease 2795 (2.1) 2355 (84.3) 440 (15.7) 
 Other chronic liver disease 33536 (24.7) 24730 (73.7) 8806 (26.3) 
 Liver cancer 39486 (29.0) 17934 (45.4) 21552 (54.6) 
  
Number of contributory causes of death  <0.001
 0 33804 (24.9) 17131 (50.7) 16673 (49.3) 
 1 44154 (32.5) 29860 (67.6) 14294 (32.4) 
 2 32193 (23.7) 23368 (72.6) 8825 (27.4) 
 3 15257 (11.2) 11753 (77.0) 3504 (23.0) 
 4+ 10545 (7.8) 8809 (83.5) 1736 (16.5) 
  
Contributory cause of death  
Influenza and Pneumonia  <0.001
   With 17304 (12.7) 14070 (81.3) 3234 (18.7) 
   Without 118649 (87.3) 76851 (64.8) 41798 (35.2) 
Esophageal varices (EV)  0.129
   With 9529 (7.0) 6440 (67.6) 3089 (32.4) 
   Without 126424 (93.0) 84481 (66.8) 41943 (33.2) 
 Cardiovascular disease  0.471
   With 9429 (6.9) 6274 (66.5) 3155 (33.5) 
   Without 126524 (93.1) 84647 (66.9) 41877 (33.1) 
Cancer (non-liver cancer or metastatic cancer)  <0.001
   With 9111 (6.7) 4274 (46.9) 4837 (53.1) 
   Without 126842 (93.3) 86647 (68.3) 40195 (31.7) 
Diabetes mellitus  0.655
   With 8075 (5.9) 5382 (66.7) 2693 (33.3) 
   Without 127878 (94.1) 85539 (66.9) 42339 (33.1) 
Alcohol related disorders  <0.001
   With 7671 (5.6) 4323 (56.4) 3348 (43.6) 
   Without 128282 (94.4) 86598 (67.5) 41684 (32.5) 
 Sepsis  <0.001
   With 7564 (5.6) 7335 (97.0) 229 (3.0) 
   Without 128389 (94.4) 83586 (65.1) 44803 (34.9) 
Hepatorenal syndrome (HRS)  <0.001
   With 7048 (5.2) 6709 (95.2) 339 (4.8) 
   Without 128905 (94.8) 84212 (65.3) 44693 (34.7) 
Renal disease  <0.001
   With 4923 (3.6) 4258 (86.5) 665 (13.5) 
   Without 131030 (96.4) 86663 (66.1) 44367 (33.9) 
Pulmonary disease  <0.001
   With 3709 (2.7) 2586 (69.7) 1123 (30.3) 
   Without 132244 (97.3) 88335 (66.8) 43909 (33.2) 
Peritonitis  <0.001
  With 3562 (2.6) 3429 (96.3) 133 (3.7) 
  Without 132391 (97.4) 87492 (66.1) 44899 (33.9) 
Neurological conditions  <0.001
   With 2537 (1.9) 1837 (72.4) 700 (27.6) 
   Without 133416 (98.1) 89084 (66.8) 44332 (33.2) 
Peptic ulcer disease  <0.001
   With 1108 (0.8) 817 (73.7) 291 (26.3) 
   Without 134845 (99.2) 90104 (66.8) 44741 (33.2) 
  Dementia  <0.001
   With 891 (0.7) 473 (53.1) 418 (46.9) 
   Without 135062 (99.3) 90448 (67.0) 44614 (33.0) 
Ascites  0.001
   With 811 (0.6) 587 (72.4) 224 (27.6) 
   Without 135142 (99.4) 90334 (66.8) 44808 (33.2) 
Encephalopathy  <0.001
   With 472 (0.3) 404 (85.6) 68 (14.4) 
   Without 135481 (99.7) 90517 (66.8) 44964 (33.2) 
Hepatopulmonary syndrome (HPS)  <0.001
   With 459 (0.3) 371 (80.8) 88 (19.2) 
   Without 135494 (99.7) 90550 (66.8) 44944 (33.2) 
 Connective tissue disorder  <0.001
   With 412 (0.3) 310 (75.2) 102 (24.8) 
   Without 135541 (99.7) 90611 (66.9) 44930 (33.1) 
  
Table 3. Factors associated with hospital deaths* (versus non-hospital deaths) in adult patients 
who died from liver disease in England, 2001–2014 (N=135,953) 
Variable Value Unadjusted PR 
(95% CI) 
Adjusted PR 
(95% CI) 
Age of death (ref: 18–44) 45–54 1.00 (0.99–1.01) 1.00 (0.98–1.01) 
 55–64 0.98 (0.97–1.00) 1.02 (1.01–1.03) 
 65–74 0.93 (0.92–0.94) 1.06 (1.04–1.07) 
 75+ 0.83 (0.82–0.84) 1.06 (1.04–1.07)     
Sex (ref: Male) Female 1.03 (1.02–1.03) 1.05 (1.04–1.05)     
Marital status (ref: married) Single 1.00 (0.99–1.01) 0.93 (0.92–0.94) 
 Widowed or widow from civil 
partnership 
0.93 (0.92–0.94) 0.95 (0.94–0.97) 
 Divorced, separated, or dissolved 
civil partnership 
1.01 (1.00–1.02) 0.92 (0.92–0.93) 
 Unknown or not stated 0.89 (0.86–0.93) 0.83 (0.81–0.86) 
    
Year of death (ref: 2001–2004) 2005–2008 0.97 (0.96–0.98) 0.97 (0.96–0.98) 
 2009–2014 0.89 (0.88–0.90) 0.91 (0.90–0.92) 
  
IMD quintile (ref: 1, most deprived) 2 0.98 (0.97–0.99) 1.00 (0.99–1.01) 
 3 0.96 (0.95–0.97) 1.00 (0.99–1.01) 
 4 0.93 (0.92–0.94) 0.98 (0.97–0.99) 
 5 (least deprived) 0.92 (0.91–0.93) 0.98 (0.97–0.99) 
    
Settlement (ref: Urban) Rural 0.95 (0.94–0.96) 0.99 (0.98–1.00) 
   
Residential region (ref: London) South East 0.95 (0.94–0.97) 0.95 (0.94–0.96) 
 South West 0.94 (0.93–0.96) 0.95 (0.93–0.96) 
 East of England 0.94 (0.93–0.96) 0.95 (0.94–0.97) 
 East Midlands 0.97 (0.96–0.99) 0.96 (0.94–0.97) 
 West Midlands 1.02 (1.01–1.04) 0.98 (0.96–0.99) 
 Yorkshire and The Humber 0.98 (0.97–1.00) 0.97 (0.95–0.98) 
 North East 0.99 (0.98–1.01) 0.98 (0.96–1.00) 
 North West 1.00 (0.99–1.02) 0.98 (0.96–0.99) 
  
Underlying cause of death (ref: 
alcoholic liver disease) 
Fatty liver disease 0.53 (0.51–0.54) 0.52 (0.50–0.54) 
 Viral liver disease 1.07 (1.05–1.09) 0.96 (0.95–0.98) 
 Other chronic liver disease 0.94 (0.93–0.94) 0.85 (0.84–0.86) 
 Liver cancer 0.58 (0.57–0.58) 0.61 (0.60–0.61) 
   
Number of contributory causes of 
death (ref: 0) 
1 1.33 (1.32–1.35) 1.20 (1.18–1.21) 
 2 1.43 (1.41–1.45) 1.24 (1.22–1.26) 
 3 1.52 (1.50–1.54) 1.32 (1.31–1.34) 
 4+ 1.65 (1.63–1.67) 1.45 (1.42–1.47) 
    
Contributory cause of death    
Sepsis With vs without 1.49 (1.48–1.50) 1.24 (1.23–1.25) 
Hepatorenal syndrome With vs without 1.46 (1.45–1.47) 1.22 (1.21–1.22) 
Peritonitis With vs without 1.46 (1.45–1.47) 1.18 (1.17–1.20) 
Renal disease With vs without 1.30 (1.29–1.32) 1.11 (1.10–1.13) 
Influenza and Pneumonia With vs without 1.26 (1.24–1.27) 1.08 (1.07–1.09) 
Hepatopulmonary syndrome With vs without 1.21 (1.16–1.26) 1.07 (1.03–1.12) 
Encephalopathy With vs without 1.28 (1.23–1.33) 1.06 (1.02–1.10) 
Neurological conditions With vs without 1.08 (1.06–1.11) 1.00 (0.98–1.02) 
Connective tissue disease With vs without 1.13 (1.06–1.19) 0.99 (0.94–1.05) 
Pulmonary disease With vs without 1.04 (1.02–1.07) 0.94 (0.92–0.96) 
Peptic ulcer disease With vs without 1.10 (1.07–1.14) 0.93 (0.90–0.96) 
Ascites With vs without 1.08 (1.04–1.13) 0.85 (0.81–0.88) 
Cancer (non-liver or metastatic 
cancer) 
With vs without 0.69 (0.67–0.70) 0.80 (0.78–0.81) 
Dementia With vs without 0.79 (0.75–0.84) 0.77 (0.73–0.82) 
Alcohol related disorders With vs without 0.83 (0.82–0.85) 0.67 (0.66–0.69) 
* The results were derived from modified Poisson regression models, adjusting the listed variables.  Only those were statistically 
significant in bivariate analysis were included in the multivariate analysis. 
 
